LC–MS for biotherapeutics research: an interview with Timothy Olah

In this interview we talk to Timothy Olah (Bristol-Myers Squibb) about his research and role as Group Director. He discusses his group’s responsibility for developing quantitative methods to measure novel therapeutics and biomarkers in discovery. The goal for his research is to identify key data to validate targets and identify compounds. Tim talks about the regulation of biomarkers and the importance of advancing the methodologies for further studies. He states that once the team identify what is needed to measure and the appropriate technology/workflow it allows them to determine if the method is sufficient to support the sample. Tim concludes the interview by discussing where he hopes the field will be in 5–10 years’ time and talks about his passion and responsibility to produce good quality data and eradicate fake news.

Related links:

• An author’s perspective: Ragu Ramanathan on an LC–MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting polypeptide biomarkers
• Opportunities and challenges for hybrid immunoaffinity LC–MS approach for quantitative analysis of protein biomarkers
• Biomarker quantification: the case for the surrogate analyte approach

If you liked this interview, you might also like:

Allena Ji on the challenges of targeted biomarker quantitation by LC–MS
Novel ADME biomarkers and HRMS move new medicines to patients faster
Pegah Jalili’s insight into biomarker discovery